Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
 & Lead Plaintiff Deadline – January 22, 2018 - EconoTimes)
NEW YORK, Jan. 05, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against OvaScience, Inc. (OVAS) ("OvaScience" or the "Company") (NASDAQ:OVAS) and certain of its officers, on behalf of shareholders who purchased OvaScience common stock directly in the Company’s January 8, 2015 Secondary Offering. Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ovas.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.
The complaint alleges that Defendants violated provisions of the Securities Act by issuing false and misleading statements and/or failed to disclose that: (1) the very science behind AUGMENT was untested and in doubt; (2) the patients that had received OvaScience’s AUGMENT procedure in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without the Company’s AUGMENT procedure; (3) the Company had not chosen to undertake its studies outside of the United States, but was forced to as it did not want to meet stringent and expensive federal regulations; and (4) the Company was far from being profitable, or even approaching profitability.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ovas or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in OvaScience you have until January 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
